Evidence map›Paper›PMID 33381305›Full record

ArticleVirus evolution2020

Preadaptation of pandemic GII.4 noroviruses in unsampled virus reservoirs years before emergence.

Christopher Ruis, Lisa C Lindesmith, Michael L Mallory, Paul D Brewer-Jensen, Josephine M Bryant, Veronica Costantini, Christopher Monit, Jan Vinjé, Ralph S Baric, Richard A Goldstein and 1 more

Abstract read
In one paragraph

Article in Virus evolution, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Global trends in norovirus genotype distribution among medically attended children with acute gastroenteritis, 2020-2025.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2026
    Article
  2. Article
  3. Understanding patterns of variant emergence and spread in an ongoing epidemic.medRxiv : the preprint server for health sciences · 2026
    Article
  4. Article
  5. Emergence of Novel Norovirus GII.4 Variant.Emerging infectious diseases · 2024
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Christopher RuisDivision of Infection and Immunity, University College London, London WC1E 6BT, UK.ORCID 0000-0003-0977-5534
Lisa C LindesmithDepartment of Epidemiology, University of North Carolina, Chapel Hill, NC, USA.
Michael L MalloryDepartment of Epidemiology, University of North Carolina, Chapel Hill, NC, USA.
Paul D Brewer-JensenDepartment of Epidemiology, University of North Carolina, Chapel Hill, NC, USA.
Josephine M BryantDivision of Infection and Immunity, University College London, London WC1E 6BT, UK.
Veronica CostantiniDivision of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.ORCID 0000-0002-1532-4345
Christopher MonitDivision of Infection and Immunity, University College London, London WC1E 6BT, UK.
Jan VinjéDivision of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Ralph S BaricDepartment of Epidemiology, University of North Carolina, Chapel Hill, NC, USA.
Richard A GoldsteinDivision of Infection and Immunity, University College London, London WC1E 6BT, UK.ORCID 0000-0001-5148-4672
Judith BreuerDivision of Infection and Immunity, University College London, London WC1E 6BT, UK.

Funding

Translational CoreU19AI109761 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SHEPARD, KENNETH L · 2014 to 2018
$32.6M
Antibody Landscape following Human Norovirus Infection and VaccinationR01AI148260 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BARIC, RALPH S · 2020 to 2024
$3.7M
Biotechnology and Biological Sciences Research Council BB/P007562/1NIAID NIH HHS R01 AI148260NIAID NIH HHS U19 AI109761Wellcome Trust 203268/Z/16/Z
6 · The paper itself

Abstract

The control of re-occurring pandemic pathogens requires understanding the origins of new pandemic variants and the factors that drive their global spread. This is especially important for GII.4 norovirus, where vaccines under development offer promise to prevent hundreds of millions of annual gastroenteritis cases. Previous studies have hypothesized that new GII.4 pandemic viruses arise when previously circulating pandemic or pre-pandemic variants undergo substitutions in antigenic regions that enable evasion of host population immunity, as described by conventional models of antigenic drift. In contrast, we show here that the acquisition of new genetic and antigenic characteristics cannot be the proximal driver of new pandemics. Pandemic GII.4 viruses diversify and spread over wide geographical areas over several years prior to simultaneous pandemic emergence of multiple lineages, indicating that the necessary sequence changes must have occurred before diversification, years prior to pandemic emergence. We confirm this result through serological assays of reconstructed ancestral virus capsids, demonstrating that by 2003, the ancestral 2012 pandemic strain had already acquired the antigenic characteristics that allowed it to evade prevailing population immunity against the previous 2009 pandemic variant. These results provide strong evidence that viral genetic changes are necessary but not sufficient for GII.4 pandemic spread. Instead, we suggest that it is changes in host population immunity that enable pandemic spread of an antigenically preadapted GII.4 variant. These results indicate that predicting future GII.4 pandemic variants will require surveillance of currently unsampled reservoir populations. Furthermore, a broadly acting GII.4 vaccine will be critical to prevent future pandemics.

Indexed as

antigenic changephylodynamicsphylogeneticsserology

Identifiers

PMID33381305
PMCPMC7751145

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.